Role of Ubiquitin-specific Proteases in Hepatocellular Carcinoma Pathogenesis-Reference-Cited by-全球学者库

Role of Ubiquitin-specific Proteases in Hepatocellular Carcinoma Pathogenesis

Published:2024-01-03 Issue: Volume:24 Page:
ISSN:1568-0266
Container-title:Current Topics in Medicinal Chemistry
language:en
Short-container-title:CTMC

Author:

Zhang Xinwen¹²,Jin Jiamin¹²³⁴,Cong Jiacheng¹³,Chen Siqi¹²⁵,Wang Ting¹⁴,Gao Bin¹⁴,Huang Guanlin¹⁴,Huang Zhiqiang¹⁴,Zhang Juzheng¹⁴,Wang Zhenran¹²,Yang Jinfeng¹³

Affiliation:

1. Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, China

2. Department of Gastrointestinal Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China

3. Department of Immunology, Guilin Medical University, Guilin, Guangxi, China

4. Guangxi Health Commission Key Laboratory of Tumor Immunology and Receptor-Targeted Drug Basic Research, Guilin Medical University, Guilin, Guangxi, China

5. Department of Oral Bioscience, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

Abstract

Abstract: Signaling pathways in hepatocellular carcinoma are primarily mediated by the phosphorylation and ubiquitination of post-translational proteins. In mammalian cells, ubiquitin-specific proteases (USPs) account for the majority of protein deubiquitination activities. In addition to transcriptional and post-translational regulation, ubiquitination plays an important role in the regulation of key proteins. There is a possibility that altered biological processes may lead to serious human diseases, including cancer. Recent studies have revealed the role of USPs in hepatocellular carcinoma tumorigenesis. The purpose of this review is to summarize the involvement of this class of enzymes in the regulation of cell signaling in hepatocellular carcinoma and the therapeutic development of inhibitors that target USPs, which may lead to novel therapies to treat hepatocellular carcinoma.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine